infect
pandem
season
influenza
viru
caus
rapid
onset
variou
symptom
includ
fever
sore
throat
cough
gener
fatigu
influenza
viru
infect
complic
pneumonia
brain
edema
exacerb
chronic
pulmonari
diseas
influenza
vaccin
reduc
mortal
rate
elderli
peopl
chronic
obstruct
pulmonari
diseas
copd
vaccin
influenza
also
recommend
prevent
sever
side
effect
influenza
exacerb
bronchial
asthma
clinic
use
antiinfluenza
drug
includ
neuraminidas
inhibitor
oseltamivir
zanamivir
benefici
uncompl
pandem
season
human
influenza
infect
howev
sever
patient
pandem
influenza
viru
infect
die
pneumonia
multiorgan
system
failur
despit
intens
drug
treatment
includ
neuraminidas
inhibitor
steroid
patient
infect
highli
pathogen
influenza
virus
experi
increas
viral
replic
subsequ
hypercytokinemia
oseltamivirresist
influenza
viru
infect
also
report
type
season
influenza
caus
sever
diseas
immunocompromis
patient
therefor
develop
drug
antiinfluenza
antiinflammatori
effect
need
homma
ohuchi
show
sendai
viru
activ
trypsin
cleav
viral
surfac
glycoprotein
fusion
protein
f
inact
precursor
heterodim
cleav
protein
fuse
viral
envelop
host
cell
membran
induc
viral
gene
enter
host
cell
subsequ
report
demonstr
trypsin
host
proteas
cleav
surfac
glycoprotein
import
membran
fusion
contribut
spread
infect
pathogen
mani
type
virus
includ
paramyxovirus
influenza
viru
serin
proteas
trypsin
transmembran
proteas
serin
member
tmprss
human
trypsinlik
proteas
hat
also
known
import
exampl
host
proteas
respons
proteolyt
cleavag
influenza
viru
hemagglutinin
ha
essenti
viral
gene
entri
cell
start
viral
replic
serin
proteas
inhibitor
aprotinin
similar
agent
leupeptin
camostat
suppress
viru
ha
cleavag
reduc
replic
influenza
virus
singl
arginin
ha
cleavag
site
effect
proteas
inhibitor
includ
aprotinin
gabex
camostat
studi
madin
darbi
canin
kidney
mdck
cell
mice
influenza
viru
infect
zhirnov
et
al
show
viral
replic
human
adenoid
epitheli
cell
also
inhibit
aprotinin
anoth
serin
proteas
inhibitor
sivelestat
use
treat
patient
acut
respiratori
distress
syndrom
howev
inhibitori
effect
serin
proteas
inhibitor
clinic
use
influenza
viral
replic
product
inflammatori
mediat
human
tracheal
bronchial
epitheli
cell
first
target
infect
studi
studi
primari
cultur
human
tracheal
epitheli
hte
cell
retain
function
origin
tissu
infect
pandem
influenza
viru
season
influenza
viru
effect
serin
proteas
inhibitor
viral
replic
cytokin
releas
cell
examin
human
tracheal
surfac
epitheli
cell
hte
cell
isol
cultur
mixtur
dulbecco
modifi
eagl
medium
dmem
ham
medium
contain
ultros
g
usg
serum
substitut
describ
previous
trachea
cell
cultur
obtain
patient
death
age
yr
femal
male
studi
approv
tohoku
univers
ethic
committe
madin
darbi
canin
kidney
mdck
cell
cultur
flask
eagl
minimum
essenti
medium
mem
contain
fetal
calf
serum
cell
plate
plate
cultur
cell
cultur
plate
mixtur
ml
medium
ml
mem
contain
viru
h
cultur
supernat
contain
viru
remov
cell
cultur
medium
contain
usg
c
co
air
supernat
collect
recov
influenza
viru
prepar
influenza
pdm
viru
nasal
swab
collect
patient
suspend
mem
medium
influenza
viru
passag
time
mdck
cell
also
use
gener
viral
stock
detect
titrat
influenza
virus
cultur
supernat
perform
use
endpoint
method
infect
replic
mdck
cell
plastic
plate
dilut
viruscontain
supernat
previous
describ
presenc
characterist
cytopath
effect
influenza
viru
determin
tcid
tcid
tissu
cultur
infect
dose
calcul
use
previous
describ
method
viral
titer
supernat
express
tcid
hosoya
et
al
compar
antivir
activ
proteas
inhibitor
includ
camostat
sivelestat
gabex
use
effect
concentr
unifi
mgml
vitro
studi
use
mdck
cell
furthermor
maxim
plasma
concentr
metabolit
camostat
also
report
ngml
therefor
compar
effect
proteas
inhibitor
studi
report
unifi
concentr
mgml
concentr
proteas
inhibitor
use
present
studi
similar
approxim
mm
mgml
molar
camostat
sivelestat
gabex
mm
mm
mm
respect
kiuml
aprotinin
mm
cell
pretreat
cultur
medium
medium
supplement
usg
contain
one
serin
proteas
inhibitor
vehicl
water
min
unless
otherwis
state
thu
treatment
serin
proteas
inhibitor
start
min
prior
infect
continu
end
experi
infect
hte
cell
influenza
viru
perform
use
previous
describ
method
stock
solut
influenza
viru
contain
one
serin
proteas
inhibitor
ad
cell
plate
ml
well
tcid
unitsml
multipl
infect
moi
tcid
unitscel
stock
solut
influenza
viru
contain
inhibitor
vehicl
prepar
dilut
viral
stock
tcid
unitsml
viru
cultur
medium
contain
inhibitor
vehicl
stock
solut
influenza
viru
contain
inhibitor
vehicl
ad
cell
infect
h
incub
viral
solut
remov
cell
rins
phosphat
buffer
salin
pb
cultur
ml
fresh
medium
contain
inhibitor
vehicl
c
co
air
portion
supernat
ml
collect
day
h
day
h
infect
equal
volum
ml
fresh
medium
contain
inhibitor
vehicl
ad
cell
cultur
entir
supernat
volum
ml
collect
day
h
infect
camostat
strong
inhibitori
effect
viral
titer
preliminari
experi
concentrationdepend
effect
camostat
studi
cell
treat
camostat
concentr
rang
mgml
mgml
use
method
viral
rna
cell
measur
confirm
differ
magnitud
viral
replic
twostep
realtim
quantit
revers
transcript
rt
pcr
assay
perform
use
taqman
gene
express
master
mix
appli
biosystem
bedford
ca
usa
describ
previous
primer
taqman
probe
virus
design
previous
report
express
viral
rna
normal
constitut
express
bactin
mrna
inhibitori
effect
camostat
ha
cleavag
serin
proteas
hte
cell
examin
previous
describ
cell
infect
influenza
pdm
viru
moi
min
cultur
h
c
co
air
cell
treat
camostat
concentr
rang
mgml
mgml
min
preto
h
postinfect
h
post
infect
viral
protein
supernat
lyse
sdspage
sampl
buffer
contain
nacalai
tesqu
kyoto
japan
mix
supernat
buffer
heat
c
min
protein
separ
sdspage
gel
transfer
pvdf
membran
soak
phosphat
buffer
salin
tween
pbst
contain
skim
milk
h
room
temperatur
rt
block
blot
incub
monoclon
antiha
antibodi
gift
e
takashita
niid
primari
antibodi
h
rt
incub
peroxidaseconjug
polyclon
goat
antimous
igg
biorad
secondari
antibodi
h
rt
protein
detect
ecl
prime
western
blot
detect
reagent
ge
healthcar
accord
manufactur
instruct
express
mrna
hat
measur
use
rtpcr
method
describ
quantif
influenza
viru
rna
util
primer
design
previous
indirect
immunofluoresc
assay
perform
report
previous
cell
fix
paraformaldehyd
pb
min
rt
fix
cell
incub
monoclon
genetex
genetex
primari
antibodi
h
rt
incub
alexa
fluor
goat
antimous
igg
molecular
probe
secondari
antibodi
nuclei
stain
molecular
probe
cell
observ
laser
scan
confoc
microscop
carl
zeiss
imag
captur
analysi
process
perform
use
softwar
carl
zeiss
photoshop
adob
interleukin
il
interferon
ifn
g
tumor
necrosi
factor
tnf
level
supernat
measur
use
elisa
measur
ifng
chemiluminesc
enzym
immunoassay
cleia
measur
tnfa
result
express
mean
sem
statist
analysi
perform
use
twoway
repeat
measur
analysi
varianc
anova
comparison
viral
titer
viral
rna
cytokin
releas
tmprsss
mrna
express
two
group
student
ttest
mannewhitney
utest
perform
subsequ
posthoc
analys
perform
use
bonferroni
method
analys
valu
p
consid
signific
experi
use
cultur
hte
cell
n
refer
number
donor
trachea
cultur
epitheli
cell
obtain
influenza
pdm
viru
detect
supernat
h
viral
titer
progress
increas
h
day
h
infect
fig
viral
titer
increas
day
observ
viral
titer
consist
across
cultur
replic
day
fig
human
tracheal
epitheli
hte
cell
treat
camostat
mgml
min
infect
titer
influenza
pdm
viru
supernat
significantli
reduc
day
infect
fig
similarli
serin
proteas
inhibitor
studi
gabex
mgml
aprotinin
kiuml
also
reduc
titer
influenza
pdm
viru
supernat
tabl
contrast
sivelestat
mgml
reduc
titer
influenza
pdm
viru
tabl
season
influenza
viru
also
detect
supernat
h
viral
titer
increas
day
observ
viral
titer
consist
across
cultur
replic
day
fig
camostat
mgml
reduc
titer
season
influenza
viru
supernat
day
infect
fig
sivelestat
mgml
gabex
mgml
aprotinin
kiuml
tabl
inhibitori
effect
camostat
titer
pdm
virus
supernat
greater
compar
concentr
approxim
mm
sivelestat
gabex
aprotinin
tabl
titer
influenza
pdm
virus
cell
treat
camostat
mgml
min
infect
differ
titer
cell
treat
camostat
infect
fig
b
also
test
camostat
possibl
cytotox
hte
cell
number
detach
cell
supernat
well
treat
camostat
day
differ
number
hte
cell
pretreat
camostat
min
infect
titer
influenza
similarli
camostat
decreas
titer
influenza
viru
supernat
concentrationdepend
manner
signific
reduct
observ
mgml
higher
concentr
fig
sivelestat
gabex
reduc
influenza
viru
titer
mgml
lower
concentr
data
shown
rna
replic
pdm
influenza
virus
increas
time
maximum
viral
rna
express
hte
cell
observ
day
h
infect
previous
describ
data
shown
cell
pretreat
camostat
mgml
min
infect
signific
reduct
rna
pdm
virus
cell
observ
day
infect
tabl
data
day
day
day
shown
similarli
sivelestat
mgml
gabex
mgml
aprotinin
kiuml
also
reduc
rna
replic
virus
tabl
inhibitori
effect
camostat
rna
replic
influenza
pdm
virus
cell
greater
sivelestat
gabex
observ
similar
concentr
approxim
mm
tabl
furthermor
inhibitori
effect
camostat
rna
replic
viru
greater
aprotinin
contrast
inhibitori
effect
camostat
rna
replic
pdm
viru
differ
effect
aprotinin
tabl
determin
whether
camostat
inhibit
cleav
ha
hte
cell
infect
pdm
viru
moi
tcid
unitscel
incub
h
c
without
mgml
camostat
progeni
viru
cultur
supernat
analyz
immunoblot
antiha
monoclon
antibodi
recogn
absenc
camostat
cleav
subunit
predomin
uncleav
detect
fig
contrast
amount
cleav
subunit
reduc
camostat
concentr
increas
amount
uncleav
correspondingli
increas
fig
indirect
immunofluoresc
assay
hte
cell
confirm
express
protein
cell
membran
cytoplasm
stain
orang
fig
b
nucleu
contrast
signific
stain
observ
control
treatment
primari
antibodi
protein
omit
data
shown
primari
cultur
hte
cell
express
mrna
hat
express
mrna
express
ratio
compar
bactin
mrna
greater
mrna
fig
mrna
express
differ
treatment
cell
camostat
chang
express
mrna
fig
signific
amount
detect
supernat
prior
viral
infect
tabl
day
sham
infect
data
shown
level
increas
infect
pdm
influenza
virus
tabl
maximum
level
observ
day
infect
two
strain
influenza
virus
data
day
day
day
shown
rel
amount
rna
express
compar
maximum
influenza
viral
rna
day
h
cell
treat
vehicl
control
result
report
mean
sem
n
signific
differ
compar
viral
infect
alon
indic
p
p
p
signific
differ
valu
cell
treat
camostat
indic
p
p
p
tabl
aprotinin
also
reduc
concentr
infect
pdm
influenza
viru
tabl
contrast
sivelestat
gabex
reduc
concentr
infect
pdm
influenza
virus
aprotinin
reduc
concentr
infect
influenza
viru
tabl
concentr
tnfa
detect
level
pgml
prior
viral
infect
increas
infect
pdm
influenza
virus
tabl
treatment
camostat
aprotinin
reduc
concentr
tnfa
supernat
day
infect
pdm
influenza
virus
tabl
contrast
sivelestat
reduc
concentr
infect
pdm
influenza
virus
inhibitori
effect
camostat
concentr
tnfa
supernat
greater
sivelestat
gabex
similar
concentr
tabl
similarli
inhibitori
effect
camostat
concentr
tnfa
supernat
greater
aprotinin
infect
pdm
influenza
viru
tabl
contrast
inhibitori
effect
camostat
concentr
tnfa
differ
aprotinin
infect
influenza
viru
studi
show
camostat
serin
proteas
inhibitor
use
treat
patient
pancreat
reduc
replic
influenza
pdm
virus
primari
human
tracheal
epitheli
hte
cell
retain
function
tissu
origin
judg
viral
titer
viral
rna
level
type
serin
proteas
inhibitor
includ
gabex
aprotinin
also
reduc
viral
titer
rna
level
cell
sivelestat
reduc
viral
rna
level
camostat
reduc
cleavag
influenza
viru
precursor
protein
subunit
cell
express
hat
protein
cell
membran
cytoplasm
well
mrna
find
suggest
serin
proteas
inhibitor
may
inhibit
replic
influenza
viru
hte
cell
inhibit
ha
cleavag
host
proteas
camostat
aprotinin
also
reduc
concentr
cytokin
tnfa
supernat
among
proteas
inhibitor
studi
camostat
may
potent
inhibitor
influenza
viru
replic
inflammatori
cytokin
product
viral
replic
express
human
nasal
tracheal
mucosa
distal
airway
lung
swine
airway
epithelium
express
human
colon
cancer
cell
line
express
human
trachea
swine
airway
epithelium
report
find
hte
cell
express
consist
report
confirm
hte
cell
express
report
affect
influenza
viru
infect
camostat
reduc
cleavag
pandem
influenza
viru
precursor
protein
subunit
contrast
camostat
reduc
mrna
level
proteas
find
suggest
camostat
might
inhibit
replic
influenza
virus
inhibit
proteas
activ
rather
reduc
proteas
mrna
level
furthermor
amount
mrna
express
therefor
intracellular
protein
express
may
greater
serin
proteas
inhibitor
aprotinin
also
inhibit
mucin
product
airway
epitheli
cell
line
action
observ
aprotinin
reduc
influenza
viru
replic
howev
measur
activ
proteas
studi
requir
clarifi
type
serin
proteas
act
influenza
viru
infect
human
airway
epitheli
cell
present
studi
treatment
camostat
increas
number
detach
cell
concentr
ldh
supernat
reduc
viabil
attach
cell
camostat
mgml
mm
inhibit
action
trypsin
report
hosoya
et
al
inhibit
influenza
viru
infect
mdck
cell
without
cytotox
find
suggest
camostat
cytotox
cell
larg
reduct
viru
titer
result
effect
proteas
activ
cytotox
camostat
inhibit
sodium
channel
function
human
bronchial
epitheli
cell
effect
revers
addit
excess
trypsin
howev
examin
effect
camostat
ion
transport
could
affect
ph
acid
endosom
virus
releas
rnp
contain
viral
rna
cytoplasm
furthermor
activ
spike
protein
sever
acut
respiratori
syndrom
coronaviru
sarscov
cell
surfac
camostat
inhibit
infect
sarscov
find
camostat
inhibit
replic
influenza
viru
inhibit
activ
proteas
includ
consist
report
present
studi
whether
cell
preincub
camostat
affect
viral
titer
supernat
suggest
pretreat
camostat
may
addit
effect
camostat
gabex
inhibit
lipopolysaccharid
lp
induc
tnf
releas
macrophag
also
develop
influenza
pneumonia
mice
inhibit
cytokin
product
includ
aprotinin
reduc
express
human
umbil
vein
endotheli
cell
myocardi
gene
express
cardiac
ischemia
reperfus
rat
show
reduc
product
tnfa
associ
diseas
symptom
sever
influenzainfect
patient
cell
damag
find
suggest
serin
proteas
inhibitor
antiinflammatori
effect
lung
airway
organ
kosai
et
al
report
gabex
suppress
influenza
pneumonia
product
mous
lung
reduc
viral
titer
similarli
mm
mgml
gabex
reduc
product
lpsstimul
peripher
blood
mononuclear
cell
contrast
found
mgml
gabex
reduc
influenza
viral
titer
though
mgml
find
suggest
concentr
serin
proteas
includ
gabex
requir
inhibit
influenza
viru
replic
may
differ
need
reduc
product
similarli
potenc
serin
proteas
inhibit
may
differ
among
cell
function
type
cell
studi
agent
studi
although
mechan
uncertain
sivelestat
report
inhibit
neutrophil
elastas
type
proteas
trypsin
gabex
also
inhibit
sever
type
proteas
includ
trypsin
inactiv
extracellular
neutrophil
elastas
contrast
camostat
inhibit
sever
type
serin
proteas
includ
trypsin
therefor
broad
rang
inhibitori
effect
camostat
varieti
serin
proteas
trypsinlik
proteas
may
contribut
potent
inhibitori
effect
present
studi
aprotinin
also
inhibit
wide
rang
proteas
includ
trypsin
neutrophil
elastas
howev
reason
differenti
inhibit
viral
replic
aprotinin
camostat
unclear
potenc
camostat
gabex
inhibitor
influenza
viru
replic
primari
cultur
hte
cell
observ
time
greater
observ
mdck
cell
hosoya
et
al
coot
et
al
show
camostat
inhibit
sodium
channel
function
human
bronchial
epitheli
cell
show
similar
concentr
ngml
ngml
respect
influenza
viru
replic
hte
cell
inhibit
precis
reason
differ
potenc
inhibitori
effect
among
cell
type
uncertain
greater
express
level
tracheal
epitheli
cell
report
mgml
leupeptin
inhibit
viru
infect
mdck
cell
concentr
proteas
inhibitor
requir
inhibit
influenza
viru
infect
may
differ
among
differ
type
epitheli
cell
calcul
molecular
weight
drug
mgml
camostat
sivelestat
gabex
kiuml
aprotinin
approxim
mm
result
tabl
therefor
suggest
camostat
among
proteas
inhibitor
studi
may
potent
inhibitor
influenza
viru
replic
consequ
inflammatori
cytokin
product
result
present
studi
show
camostat
reduc
influenza
viru
replic
hte
cell
consist
report
lee
et
al
show
similar
find
mice
previou
report
demonstr
metabolit
camostat
activ
similar
camostat
reach
maxim
plasma
concentr
ngml
oral
administr
mg
camostat
human
subject
approxim
maxim
concentr
maintain
min
present
studi
titer
pdm
influenza
virus
supernat
reduc
camostat
concentr
ngml
find
suggest
camostat
reduc
releas
pandem
season
influenza
virus
supernat
hte
cell
typic
clinic
concentr
effect
serin
inhibitor
viral
titer
supernat
consist
effect
inhibitor
viral
rna
level
cell
although
supernat
contain
serin
proteas
inhibitor
therefor
viral
titer
measur
present
studi
might
indic
true
viral
content
supernat
portion
supernat
ml
collect
day
h
h
infect
replac
equal
ml
volum
fresh
medium
contain
camostat
entir
supernat
volum
ml
collect
day
h
infect
measur
final
concentr
camostat
howev
ad
fresh
medium
contain
camostat
two
differ
time
point
h
h
cell
incub
humidifi
incub
found
medium
volum
chang
significantli
h
infect
therefor
addit
fresh
camostat
medium
would
maintain
final
concentr
camostat
mgml
howev
increas
concentr
due
cellular
uptak
camostat
rule
could
look
chang
concentr
might
result
cellular
uptak
camostat
demonstr
inhibitori
effect
camostat
influenza
viral
replic
infectioninduc
product
inflammatori
cytokin
use
human
tracheal
epitheli
cell
camostat
use
treat
chronic
pancreat
alreadi
clear
obstacl
market
approv
includ
safeti
issu
therefor
use
camostat
influenza
patient
anim
experi
requir
confirm
antivir
effect
low
toxic
ultim
clinic
trial
patient
assess
clinic
benefit
influenza
patient
conclus
human
tracheal
epitheli
cell
express
serin
proteas
includ
administ
typic
clinic
concentr
camostat
serin
proteas
inhibitor
may
reduc
replic
influenza
viru
product
inflammatori
cytokin
human
airway
epitheli
cell
